Evaxion Biotech A/S (EVAX)
After hours:
| Previous close | 4.0100 |
| Open | 4.0500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.8900 - 4.0500 |
| 52-week range | 2.8240 - 18.5000 |
| Volume | |
| Avg. volume | 58,468 |
| Market cap | 20.287M |
| Beta (5Y monthly) | -0.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -8.1000 |
| Earnings date | 29 May 2024 - 03 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.75 |
Globe NewswireEvaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosingFavorable safety profile confirmedTrial on track for one-year clinical efficacy readout in Q3 2024 COPENHAGEN, Denmark, April 17, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces that the first patient in its EVX-01 Phase 2 trial in metastatic melanoma
ZacksEvaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
Evaxion (EVAX) gains 20% on positive results from the pre-clinical studies of its EVX-B1 vaccine candidate in large non-rodent animals, which is being developed to treat S. aureus infection.
Insider MonkeyEvaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript
Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript April 2, 2024 Evaxion Biotech A/S isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Christian Kanstrup: Hello, everyone, and a very warm welcome to this Evaxion Business Update Conference call on the […]
